NDA 022055 · Almirall
Altabax
Retapamulin · Topical
NovelDiscontinuedLast checked: Nov 20, 2026Latest source record: Sep 10, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2007
Apr 12, 2007
Approved uses
1
Original approval plus efficacy supplements
Registered trials
16
6 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 12, 2007 Original approval · Type 1 - New Molecular Entity NovelPediatric Medical ReviewPediatric Clinical Pharmacology ReviewLabel
1 products under this application
- ALTABAX · RETAPAMULIN 1% · OINTMENT, TOPICAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Retapamulin" as an intervention, any sponsor and status, largest first.
- Topical SB-275833 Ointment, 1% For The Treatment Of ImpetigoPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT00133874 · 520 participants · Start Apr 2005 · Primary completion Sep 2005
Drug: SB-275833 ointment, 1% · For: Skin Infections, Bacterial
Sites: Winnipeg, Canada; St. John's, Canada; Brampton, Canada · 69 sites in all
- Retapamulin Versus Placebo in Secondarily-Infected Traumatic Lesions (SITL)Pivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT00684177 · 508 participants · Start May 2008 · Primary completion Oct 2009
Drug: Retapamulin Ointment, 1%; Placebo ointment · For: Skin Infections, Bacterial
Sites: Tucson, Arizona; Anaheim, California; Fresno, California · 54 sites in all
- Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With ImpetigoPivotal-lookingCompleted
Ferrer Internacional S.A.Industry
NCT01397461 · 465 participants · Start Mar 2012 · Primary completion Dec 2012
Drug: ozenoxacin placebo; retapamulin 1% ointment and 1 more · For: Impetigo
Sites: Augsburg, Germany; Cologne, Germany; Dresden, Germany · 19 sites in all
- Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSAPivotal-lookingCompleted
Stiefel, a GSK CompanyIndustry
NCT00852540 · 410 participants · Start Apr 2009 · Primary completion Jul 2010
Drug: Retpamulin Ointment, 1%; Linezolid · For: Skin Infections, Bacterial
Sites: Anniston, Alabama; Birmingham, Alabama; Bentonville, Arkansas · 53 sites in all
- Treatment Of Impetigo With Topical SB-275833 Ointment, 1% Versus Topical Placebo OintmentPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT00133848 · 210 participants · Start Apr 2005
Drug: SB-275833 ointment, 1% · For: Impetigo
Sites: Bangalore, India; Hyderabad, India; Rome, Italy · 22 sites in all
Gary GoldenbergAcademic, hospital or other
NCT01591785 · 60 participants · Start Jan 2012 · Primary completion Aug 2012
Drug: Retapamulin 1% ointment; Placebo · For: Hand Eczema; Foot Eczema
Sites: New York, New York
GlaxoSmithKlineGSK (GSK)
NCT00555061 · 60 participants · Start Sep 2007 · Primary completion Aug 2008
Drug: Retapamulin Ointment, 1% · For: Skin Infections, Bacterial
Sites: Tuscaloosa, Alabama; Bentonville, Arkansas; Orange, California · 25 sites in all
GlaxoSmithKlineGSK (GSK)
NCT00539994 · 57 participants · Start Sep 2007 · Primary completion Jan 2008
Drug: retapamulin; Retapamulin and 1 more · For: Infections, Bacterial
Sites: San Diego, California; Honolulu, Hawaii; Baltimore, Maryland · 4 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Altabax (Retapamulin)
2024 spending
$20K
Beneficiaries
31
33 claims
Per beneficiary
$658
$22.66 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $82,491 |
| 2021 | $79,813 |
| 2022 | $87,935 |
| 2023 | $74,401 |
| 2024 | $20,396 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Interventions for impetigo.
Koning S, van der Sande R, Verhagen AP, et al. · Cochrane Database Syst Rev 2012 · Meta-Analysis, Research Support, Non-U.S. Gov't
- A comparative review of current topical antibiotics for impetigo.
Galindo E, Hebert AA · Expert Opin Drug Saf 2021 · Comparative Study, Systematic Review
- Retapamulin ointment twice daily for 5 days vs oral cephalexin twice daily for 10 days for empiric treatment of secondarily infected traumatic lesions of the skin.
Free A, Roth E, Dalessandro M, et al. · Skinmed 2006 · Comparative Study, Multicenter Study
- Ozenoxacin 1% cream in the treatment of impetigo: a multicenter, randomized, placebo- and retapamulin-controlled clinical trial.
Gropper S, Albareda N, Chelius K, et al. · Future Microbiol 2014 · Multicenter Study, Randomized Controlled Trial
- Emerging Treatment Strategies for Impetigo in Endemic and Nonendemic Settings: A Systematic Review.
Gahlawat G, Tesfaye W, Bushell M, et al. · Clin Ther 2021 · Research Support, Non-U.S. Gov't, Systematic Review
- Efficacy and tolerability of retapamulin 1% ointment for the treatment of infected atopic dermatitis: a pilot study.
Kircik LH · J Drugs Dermatol 2012 · Clinical Trial
Sponsor: Almirall
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.